1. Cohen C, Walaza S, Viboud C, Cohen AL, Madhi SA, Venter M, et al. Deaths Associated with Respiratory Syncytial and Influenza Viruses among Persons ≥5 Years of Age in HIV-Prevalent Area, South Africa, 1998–2009 - Volume 21, Number 4—April 2015 - Emerging Infectious Diseases journal - CDC. [cited 2021 Aug 6]; Available from: https://wwwnc.cdc.gov/eid/article/21/4/14-1033_article
2. Cohen C, Moyes J, Tempia S, Groome M, Walaza S, Pretorius M, et al. Mortality amongst Patients with Influenza-Associated Severe Acute Respiratory Illness, South Africa, 2009-2013. PLOS ONE. 2015 Mar 18;10(3):e0118884.
3. Jassat W, Cohen C, Tempia S, Masha M, Goldstein S, Kufa T, et al. Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study. The Lancet HIV [Internet]. 2021 Aug 4 [cited 2021 Aug 6];0(0). Available from: https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(21)00151-X/abstract
4. Boulle A, Davies M-A, Hussey H, Ismail M, Morden E, Vundle Z, et al. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis. 2020 Aug 29;
5. WHO Global Clinical Platform for COVID-19. Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection [Internet]. World Health Organization; 2021. Available from: https://apps.who.int/iris/bitstream/handle/10665/342697/WHO-2019-nCoV-Clinical-HIV-2021.1-eng.pdf
6. Venturas J, Zamparini J, Shaddock E, Stacey S, Murray L, Richards GA, et al. Comparison of outcomes in HIV-positive and HIV-negative patients with COVID-19. Journal of Infection [Internet]. 2021 May 26 [cited 2021 Jun 6];0(0). Available from: https://www.journalofinfection.com/article/S0163-4453(21)00262-0/abstract
7. Patel VV, Felsen UR, Fisher M, Fazzari MJ, Ginsberg MS, Beil R, et al. Clinical Outcomes and Inflammatory Markers by HIV Serostatus and Viral Suppression in a Large Cohort of Patients Hospitalized With COVID-19. J Acquir Immune Defic Syndr. 2021 Feb 1;86(2):224–30.
8. Calligaro GL, Lalla U, Audley G, Gina P, Miller MG, Mendelson M, et al. The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: A multi-centre prospective observational study. EClinicalMedicine. 2020 Nov;28:100570.
9. Consortium Co-19 MBAt (COMBAT), Ahern DJ, Ai Z, Ainsworth M, Allan C, Allcock A, et al. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. medRxiv. 2021 May 11;2021.05.11.21256877.
10. Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, Liew F, Russell CD, Moore SC, et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Sci Immunol. 2021 Mar 10;6(57):eabg9873.
11. Vanderbeke L, Van Mol P, Van Herck Y, De Smet F, Humblet-Baron S, Martinod K, et al. Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. Nat Commun. 2021 Jul 5;12(1):4117.
12. Hanna SJ, Codd AS, Gea-Mallorqui E, Scourfield DO, Richter FC, Ladell K, et al. T cell phenotypes in COVID-19 - a living review. Oxford Open Immunology [Internet]. 2021 Jan 1 [cited 2021 Feb 20];2(iqaa007). Available from: https://doi.org/10.1093/oxfimm/iqaa007
13. Mueller AA, Tamura T, Crowley CP, DeGrado JR, Haider H, Jezmir JL, et al. Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients. Cell Rep Med. 2020 Oct 29;1(8):100144.
14. Roca O, Messika J, Caralt B, García-de-Acilu M, Sztrymf B, Ricard J-D, et al. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: The utility of the ROX index. J Crit Care. 2016 Oct;35:200–5.
15. Results — RECOVERY Trial [Internet]. [cited 2021 Sep 25]. Available from: https://www.recoverytrial.net/results
16. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol. 2009 Apr;9(4):235–45.
17. Walker B, McMichael A. The T-Cell Response to HIV. Cold Spring Harb Perspect Med. 2012 Nov;2(11):a007054.
18. McCausland MR, Juchnowski SM, Zidar DA, Kuritzkes DR, Andrade A, Sieg SF, et al. Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy. PLOS ONE. 2015 Oct 2;10(10):e0139474.
19. Riou C, Bruyn E du, Stek C, Daroowala R, Goliath RT, Abrahams F, et al. Profile of SARS-CoV-2-specific CD4 T cell response: Relationship with disease severity and impact of HIV-1 and active Mycobacterium tuberculosis co-infection [Internet]. Infectious Diseases (except HIV/AIDS); 2021 Feb [cited 2021 Mar 2]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.02.16.21251838
20. Karim F, Gazy I, Cele S, Zungu Y, Krause R, Bernstein M, et al. HIV status alters disease severity and immune cell responses in β variant SARS-CoV-2 infection wave [Internet]. 2021 Sep [cited 2021 Sep 27] p. 2020.11.23.20236828. Available from: https://www.medrxiv.org/content/10.1101/2020.11.23.20236828v2
21. Snyman J, Hwa S-H, Krause R, Muema D, Reddy T, Ganga Y, et al. Similar antibody responses against SARS-CoV-2 in HIV uninfected and infected individuals on antiretroviral therapy during the first South African infection wave. Clinical Infectious Diseases [Internet]. 2021 Sep 2 [cited 2021 Sep 28];(ciab758). Available from: https://doi.org/10.1093/cid/ciab758
22. Barbera LK, Kamis KF, Rowan SE, Davis AJ, Shehata S, Carlson JJ, et al. HIV and COVID-19: review of clinical course and outcomes. HIV Res Clin Pract. :1–17.
23. Kim H, Tanser F, Tomita A, Vandormael A, Cuadros DF. Beyond HIV prevalence: identifying people living with HIV within underserved areas in South Africa. BMJ Global Health. 2021 Apr 1;6(4):e004089.
24. Simbayi L, Zuma K, Zungu N, Moyo S, Marinda E, Jooste S, et al. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2017: towards achieving the UNAIDS 90-90-90 targets. 2019 [cited 2021 Oct 17]; Available from: https://repository.hsrc.ac.za/handle/20.500.11910/15052
25. RStudio Team. RStudio: Integrated Development for R [Internet]. RStudio, PBC, Boston, MA; 2020. Available from: http://www.rstudio.com
26. Alboukadel Kassambara, Marcin Kosinski, Przemyslaw Biecek. survminer: Drawing Survival Curves using ‘ggplot2’. R package version 048 [Internet]. Available from: https://CRAN.R-project.org/package=survminer
27. Dardis C. survMisc: Miscellaneous Functions for Survival Data [Internet]. 2018. Available from: https://CRAN.R-project.org/package=survMisc
28. Alboukadel Kassambara. ggpubr: ‘ggplot2’ Based Publication Ready Plots. R package version 040 [Internet]. 2020; Available from: https://CRAN.R-project.org/package=ggpubr
29. Yoshida K, Bartel A, Chipman JJ, Bohn J, McGowan LDa, Barrett M, et al. tableone: Create ‘Table 1’ to Describe Baseline Characteristics with or without Propensity Score Weights [Internet]. 2021 [cited 2021 Dec 9]. Available from: https://CRAN.R-project.org/package=tableone
30. Durstenfeld MS, Sun K, Ma Y, Rodriguez F, Secemsky EA, Parikh RV, et al. Impact of HIV Infection on COVID-19 Outcomes Among Hospitalized Adults in the U.S. medRxiv. 2021 Apr 7;2021.04.05.21254938.
31. Cao W, Mehraj V, Kaufmann DE, Li T, Routy J-P. Elevation and persistence of CD8 T-cells in HIV infection: the Achilles heel in the ART era. Journal of the International AIDS Society. 2016 Jan;19(1):20697.
32. Sun J, Patel RC, Zheng Q, Madhira V, Olex AL, Islam JY, et al. COVID-19 Disease Severity among People with HIV Infection or Solid Organ Transplant in the United States: A Nationally-representative, Multicenter, Observational Cohort Study [Internet]. 2021 Jul [cited 2021 Oct 20] p. 2021.07.26.21261028. Available from: https://www.medrxiv.org/content/10.1101/2021.07.26.21261028v1
33. Tesoriero JM, Swain C-AE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, et al. COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State. JAMA Netw Open. 2021 Feb 1;4(2):e2037069.
34. Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, et al. Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. The Lancet HIV [Internet]. 2021 Oct 13 [cited 2021 Oct 17];0(0). Available from: https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(21)00240-X/fulltext
35. Gupta S, Nakabo S, Blanco LP, O’Neil LJ, Wigerblad G, Goel RR, et al. Sex differences in neutrophil biology modulate response to type I interferons and immunometabolism. PNAS. 2020 Jul 14;117(28):16481–91.
36. Cai Y, Kim DJ, Takahashi T, Broadhurst DI, Yan H, Ma S, et al. Kynurenic acid may underlie sex-specific immune responses to COVID-19. Science Signaling. 2021 Jul 6;14(690):eabf8483.